GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates...
Boehringer begins enrolment in Phase II BALANCE-CF1 trial
Boehringer Ingelheim has enrolled the first patient in the Phase II BALANCE-CF study investigating an inhaled epithelial sodium channel (ENaC) inhibitor, BI 1265162, to treat cystic fibrosis.
Verona Pharma closes enrolment in Phase IIb COPD trial
UK-based biopharmaceutical firm Verona Pharma has completed patient enrolment in a Phase IIb clinical trial of nebulised ensifentrine (RPL554) to treat moderate-to-severe chronic obstructive pulmonary disease (COPD).
Nucala minimises exacerbations in eosinophilic asthma patients
GlaxoSmithKline (GSK) has reported positive results from its study of Nucala (mepolizumab) in patients with severe eosinophilic asthma.
AstraZeneca’s Breztri Aerosphere is a late-stage blockbuster
GlobalData anticipates rapid approval for AstraZeneca triple-combination therapy inhaler Breztri Aerosphere in the EU and US.
The most researched drugs in cystic fibrosis trials
GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates between January 1, 2009 and August 28, 2019.
AstraZeneca’s ETHOS trial of Breztri Aerosphere meets primary endpoint
AstraZeneca has reported positive findings from the Phase III ETHOS trial that evaluated Breztri Aerosphere for the treatment of patients with severe chronic obstructive pulmonary disease (COPD).
Knopp begins study of dexpramipexole in eosinophilic asthma patients
Knopp Biosciences has commenced patient enrolment in a Phase II clinical trial of dexpramipexole for the treatment of moderate-to-severe eosinophilic asthma.
Altavant doses first patient in ELEVATE 1 trial of PAH drug
Altavant Sciences has dosed the first patient in the ELEVATE 1 trial of its lead candidate rodatristat ethyl to treat adults with pulmonary arterial hypertension (PAH).
New respiratory syncytial virus vaccine shows promise in Phase I trial
An experimental vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) to protect against respiratory syncytial virus (RSV) has yielded positive data in a Phase I clinical trial.
Genkyotex to launch Phase II pulmonary fibrosis trial in US
French biopharmaceutical firm Genkyotex has secured US regulatory approval to conduct a Phase II clinical trial of GKT831 for the treatment of idiopathic pulmonary fibrosis (IPF).